FH Week 2025

Join us for EAS FH Week 2025!

Familial Hypercholesterolaemia (FH) is underdiagnosed, undertreated—and urgent to address. During FH Week 2025, we aim to shine a spotlight on FH, raising awareness among the general public, healthcare professionals, and policy-makers alike. Our message is clear: managing FH requires shared responsibility and strong collaboration.

Be part of the movement! Follow us on social media and help amplify the message by sharing FH-related content within your network. Don’t forget to use the hashtags:

#FHWeek, #FindFH, #FHAware, and #FHAware2025

---

FHSC: A decade of collaboration, innovation, and impact in FH care

Since its launch in 2015, the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) has grown into a truly global force, driving progress in the understanding and care of FH. What began as a small initiative has evolved into a powerful international network spanning 76 countries and 92 National Lead Investigators, with data collected on over 80,000 individuals living with FH.

This decade-long collaboration now stands as one of the largest and most impactful global efforts in cardiovascular research. The FHSC’s findings have shaped clinical perspectives worldwide, with high-impact publications featured in leading journals such as Atherosclerosis, The Lancet, The Lancet Diabetes & Endocrinology, and the European Heart Journal.

Over the years, the FHSC has delivered landmark insights and research milestones—pushing the boundaries of what we know about FH and transforming how we manage it globally.

Key research milestones include:

• The initial “call to arms” establishing the need for global FH research (Atherosclerosis, 2015)
• Documentation of the collaboration’s rationale and design (Atheroscl . Suppl., 2016)
• Comprehensive overview of FH care across 60+ countries (Atherosclerosis, 2018)
• Global perspective on FH in adults (Lancet, 2021)
• Characterisation of FH in children and adolescents (Lancet, 2024)
• Association between BMI, LLM, age and diabetes in FH patients (The Lancet Diabetes & Endocrinology, 2024)
• Analysis of overweight, obesity and CVD in FH (European Heart Journal, 2025)
• To all FHSC Publications >

The collaboration helped shape The Prague Declaration for Paediatric FH Screening, which was subsequently recognised for its excellence through inclusion in the European Union’s Best Practices Portal for Non-Communicable Disease (NCD) prevention (you can access and endorse the declaration here).

Read more about the EAS-FHSC objectives and structure >

---

Driving change, country by country: How the FHSC supports national action

At the heart of the EAS FHSC is a strong commitment to empowering national coordinating centers. By supporting the implementation of locally tailored treatment strategies, the FHSC helps countries address their unique healthcare needs—working together to reduce the global burden of familial hypercholesterolaemia (FH).

Each year, we share updates and new insights from these national efforts, showcasing how global collaboration leads to meaningful, local impact.

During FH Week 2025, we’re proud to highlight the success stories, innovative approaches, and published findings that have emerged from these initiatives.

Discover how countries are making a difference in FH care:

---

Global network & registry: get involved

Do you have an interest in FH, collect clinical and/or genetic FH data and are keen to contribute to the EAS FHSC Global Registry (CT.gov Identifier: NCT04272697)?

If so, we would like to hear from you! For enquires contact:
info@eas-fhsc.org

FHSC Coordinating Centre provides a free essential web-based resource exclusive to FHSC Investigators and their local teams to support entering and managing local-level data, and sharing data with the FHSC Global Registry. Ask the Coordinating Centre for more details.

---

FH in focus: Key publications from 2025

Dive into a curated selection of FH-related publications from the Atherosclerosis and Atherosclerosis Plus journals, showcasing the most recent research, expert perspectives, and widely read articles.

Compilation of articles from Atherosclerosis >

Compilation of articles from Atherosclerosis Plus >

---

Watch FH-related lectures from the EAS Congress 2025

Many aspects of FH are an important area of discussion for our scientific community. We have collected FH-related lectures from our latest congresses, especially from EAS Congress 2025.

Lectures related to FH from the EAS Congress >

---

EAS at the European Parliament

We are proud to share that EAS President, Prof. Børge Nordestgaard, will speak at the European Parliament on 25 September 2025 at the high-level meeting titled Cardiovascular Prevention as the Cornerstone of a Competitive Europe, Scaling Up Lipid Screening to Secure Next Generations hosted by MEP Romana Jerković and and MEP Tomislav Sokol.

The programme will include:

• A Tale of Two Declarations: Proof of Policy Impact – Prof. Børge Nordestgaard (Denmark) alongside Prof. Albert Wiegman (Netherlands) & Prof. Florian Kronenberg (Austria, online)
  How the Prague Declaration (FH paediatric screening) and Brussels International Declaration (Lp(a) testing), as part of integrated care, demonstrate that patient-led advocacy can create real momentum.

Read more >

---

Hidden in plain sight: The silent risk of Lp(a)

More than 1.4 billion people live with elevated lipoprotein(a) – a major inherited risk factor for heart disease – yet only 1–2% are tested. The Brussels Declaration on Lp(a), co-developed by global experts and policymakers, calls for urgent, coordinated action: testing, awareness, and better care.

Be loud! Endorse the declaration

Endorse the Brussels International Declaration >

---